TP53 and neoplasm: Several ongoing clinical trials are testing the safety and the efficacy of arsenic trioxide for acute myeloid leukemia, myelodysplastic syndromes, and refractory tumor with TP53 mutation (NCT03931291, NCT04214860, NCT04383938, NCT03745716, NCT04419389, NCT03588078, and NCT03072043 at ClinicalTrials.gov (accessed on 1 July 2021)).